https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48015 Wed 15 Feb 2023 09:58:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49298 Wed 06 Mar 2024 14:17:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48331 75% for each characteristic) would not modify duration based on host characteristics such as patient age or co-morbidities. ID physicians recommended longer durations than ICU physicians for all five syndromes (ID, median 10, IQR 7–14, range 1–28 days; ICU, median 7, IQR 5–10, range 2–21 days). Across all respondents, the median (IQR) duration for each syndrome was: CVC-BSI, 7 (7–10) days; bacteraemic pneumonia, 7 (7–10) days; bacteraemic UTI, 10 (7–14) days; bacteraemic IAI, 7 (7–12) days; and bacteraemic SSTI, 10 (7–14) days. Marked variation exists amongst clinicians’ recommended duration of antibiotic treatment for BSI. A proportion of clinicians recommend therapy of ≤7 days at present (33.3–59.7% across scenarios). Patient characteristics are not strongly considered in the decision on therapy duration. This survey was undertaken as preparatory work for initiation of the BALANCE study, an ongoing randomised trial comparing 7 days with 14 days of therapy for BSI, providing an evidence base to inform best clinical treatment for this patient population.]]> Tue 14 Mar 2023 16:54:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51456 50% inhibition when evaluated at 32 μg/mL compound concentration against methicillin-resistant Staphylococcus aureus. Examination of the terminal aromatic substituent via oxirane aminolysis allowed for the synthesis of three new focused libraries of afforded amino alcohols. Aromatic substituted piperidine or piperazine switched library activity from antibacterial to anti-fungal activity with ((Z)-2-(3,4-dichlorophenyl)-3-(4-(2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy)phenyl)acrylonitrile), ((Z)-2-(3,4-dichlorophenyl)-3-(4-(2-hydroxy-3-(4-(4-hydroxyphenyl)piperazin-1-yl)propoxy)-phenyl)acrylonitrile) and ((Z)-3-(4-(3-(4-cyclohexylpiperazin-1-yl)-2-hydroxypropoxy)-phenyl)-2-(3,4-dichlorophenyl)-acrylonitrile) showing >95% inhibition of Cryptococcus neoformans var. grubii H99 growth at 32 μg/mL. While (Z)-3-(4-(3-(cyclohexylamino)-2-hydroxypropoxy)phenyl)-2-(3,4-dichlorophenyl)-acrylonitrile, (S,Z)-2-(3,4-dichlorophenyl)-3-(4-(2-hydroxy-3-(piperidin-1-yl)propoxy)phenyl)acrylonitrile, (R,Z)-2-(3,4-dichlorophenyl)-3-(4-(2-hydroxy-3-(piperidin-1-yl)propoxy)phenyl)acrylonitrile, (Z)-2-(3,4-dichlorophenyl)-3-(4-(2-hydroxy-3-(D-11-piperidin-1-yl)propoxy)phenyl)-acrylonitrile, and (Z)-3-(4-(3-(4-cyclohexylpiperazin-1-yl)-2-hydroxypropoxy)-phenyl)-2-(3,4-dichlorophenyl)-acrylonitrile 32 μg/mL against Staphylococcus aureus.]]> Tue 05 Sep 2023 18:22:02 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34013 Tue 03 Sep 2019 18:31:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28967 Thu 26 Jul 2018 16:22:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42833 Thu 04 May 2023 15:13:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31374 Sat 24 Mar 2018 08:43:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1489 24 hrs [odds ratio, 4.42; 95% confidence interval, 2.42-8.10]). The mortality for patients with aspiration pneumonitis was 8.5% compared with 0.4% for those without (odds ratio, 23; 95% confidence interval, 9-60; p < .0001), and they had a significantly higher intensive care unit admission rate. The median length of stay of patients with aspiration pneumonitis was 126 hrs (interquartile range, 62-210 hrs) compared with 14.7 hrs (interquartile range, 7-23 hrs) in patients without (p < .0001). Conclusions: Our study has shown a number of risk factors in overdose patients that are associated with aspiration pneumonitis that may allow the early identification of these patients for appropriate observation and management. Patients with aspiration pneumonitis have a significantly increased mortality and length of stay in the hospital.]]> Sat 24 Mar 2018 08:28:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27293 Bacillus subtilis and Gram-negative Escherichia coli growth.]]> Sat 24 Mar 2018 07:40:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27614 Sat 24 Mar 2018 07:39:40 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24441 Sat 24 Mar 2018 07:17:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52497 Mon 16 Oct 2023 15:10:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46213 Mon 14 Nov 2022 11:58:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30269 Mon 11 Mar 2019 12:09:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51906 16-fold (from >125 μM to 15.6 μM) and greatly reduced cytotoxicity against mammalian cells (from ≤20 μM to ≥150 μM). These compounds showed significant disruption of preformed biofilms of S. aureus at micromolar concentrations.]]> Fri 22 Sep 2023 10:25:08 AEST ]]>